San Diego, Ca., USA – Innovus Pharmaceuticals, Inc., a pharmaceutical company, announced the appointment of Bassam Damaj to serve as president and CEO, and a member of the board of directors.[break]
Before joining Innovus Pharma, Dr. Damaj served as President & Chief Executive Officer of
Apricus Biosciences, Inc. from December 2009 until November 2012. Dr. Damaj also signed partnerships between Apricus Bio and leading pharmaceutical companies such as Abbott, Novartis - January 23, 2013, San Diego, Ca., USA – Innovus Pharmaceuticals, Inc., a pharmaceutical company, announced the appointment of Bassam Damaj to serve as president and CEO, and a member of the board of directors.
Article continues below
Before joining Innovus Pharma, Dr. Damaj served as President & Chief Executive Officer of
Apricus Biosciences, Inc. from December 2009 until November 2012. Dr. Damaj also signed partnerships between Apricus Bio and leading pharmaceutical companies such as Abbott, Novartis-Sandoz and Takeda.
Before Apricus Bio, Dr. Damaj was a co-founder of Bio-Quant, Inc. and served as the Chief
Executive Officer and Chief Scientific Officer and a Director of Bio-Quant’s board of directors from its inception in June 2000 until its acquisition by Apricus Biosciences in June 2011.
In addition, Dr. Damaj was the founder, Chairman, President & Chief Executive Officer of R&D Healthcare, and the co-founder of Celltek Biotechnologies. He also served as a Director of the Board of Directors at CreAgri, Inc. and was Member of Scientific Advisory Board of MicroIslet, Inc.
Dr. Damaj is the author of the Immunological Reagents and Solutions reference book, the
inventor of many patents and author of numerous peer reviewed scientific publications. Dr.
Damaj won a US Congressional award for the Anthrax Multiplex Diagnostic Test in 2003.
Dr. Damaj holds a Ph.D. degree in Immunology/Microbiology from Laval University and completed a postdoctoral fellowship in molecular oncology from McGill University. He replaces Vivian Liu, who resigned from the Company’s management team. Ms. Liu will continue to serve on the Board of Directors.
Innovus Pharma also announced that director Henry Esber Ph.D. has been appointed Chairman of the Board.
Dr. Esber has served as a Director since January 2011. In 2000, Dr. Esber co-founded Bio-Quant, Inc., the largest pre-clinical discovery contract research organization in San Diego, and served as its Senior Vice President and Chief Business Development Officer from 2000-2010. ■